15 results
DEFM14A
LABP
Landos Biopharma Inc
25 Apr 24
Proxy related to merger
5:07pm
related to privacy or cybersecurity except to remediate any security issue, to enhance data security or integrity, to comply with or improve … administrative, technical, or physical safeguards related to privacy or cybersecurity except to remediate any security issue,
A-30
to enhance data security
PREM14A
LABP
Landos Biopharma Inc
15 Apr 24
Preliminary proxy related to merger
5:18pm
respect any privacy policies, or any administrative, technical, or physical safeguards related to privacy or cybersecurity except to remediate any … any privacy policies, or any administrative, technical, or physical safeguards related to privacy or cybersecurity except to remediate any security
DEFA14A
LABP
Landos Biopharma Inc
25 Mar 24
Additional proxy soliciting materials
9:19am
or cybersecurity except to remediate any security issue, to enhance data security or integrity, to comply with or improve compliance with applicable
8-K
EX-2.1
LABP
Landos Biopharma Inc
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
8:54am
material respect any privacy policies, or any administrative, technical, or physical safeguards related to privacy or cybersecurity except
10-K
bak9b7rfz95dk7tih13
31 Mar 21
Annual report
5:03pm
424B4
jhgsqd2jbsqscq9
4 Feb 21
Prospectus supplement with pricing info
5:02pm
S-1/A
n7mo th54
28 Jan 21
IPO registration (amended)
9:12am
S-1/A
EX-1.1
n5oo 59tnjtk35lyb
28 Jan 21
IPO registration (amended)
9:12am
S-1
pl4xlef6pxgws
13 Jan 21
IPO registration
5:07pm
DRS/A
0u1ebd8
1 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
1q7gmf6v1t5r9
1 Sep 20
Draft registration statement (amended)
12:00am
DRS
4ggxq0tviyt11669oj
24 Jul 20
Draft registration statement
12:00am
- Prev
- 1
- Next